BETA DRUGS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,306 INR | -2.87% |
|
-5.33% | -11.13% |
| 2023 | Beta Drugs Limited Reports Earnings Results for the Half Year Ended September 30, 2023 | CI |
| 2023 | Beta Drugs Limited Reports Earnings Results for the Full Year Ended March 31, 2023 | CI |
| Sales 2022 | 1.84B 22.05M | Sales 2023 | 2.27B 27.24M | Capitalization | 6.03B 72.29M |
|---|---|---|---|---|---|
| Net income 2022 | 248M 2.97M | Net income 2023 | 307M 3.68M | EV / Sales 2022 | 2.98 x |
| Net Debt 2022 | 32.79M 393K | Net Debt 2023 | 11.68M 140K | EV / Sales 2023 | 2.66 x |
| P/E ratio 2022 |
21.9
x | P/E ratio 2023 |
19.6
x | Employees | 315 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 89.07% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.87% | ||
| 1 week | -5.33% | ||
| Current month | +5.88% | ||
| 1 month | +4.93% | ||
| 3 months | -5.13% | ||
| 6 months | +42.49% | ||
| Current year | -11.13% |
1 week
1 300.00
1 428.00
1 month
1 197.251 428.00
Current year
1 060.051 524.00
1 year
660.001 595.00
3 years
176.001 595.00
5 years
37.001 595.00
10 years
37.001 595.00
| Managers | Title | Age | Since |
|---|---|---|---|
Rahul Batra
CEO | Chief Executive Officer | 40 | 14-07-31 |
Varun Batra
CEO | Chief Executive Officer | 38 | 14-07-31 |
Nipun Arora
DFI | Director of Finance/CFO | 39 | 21-03-04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Balwant Singh
BRD | Director/Board Member | 54 | 14-07-31 |
Varun Batra
CEO | Chief Executive Officer | 38 | 14-07-31 |
Rahul Batra
CEO | Chief Executive Officer | 40 | 14-07-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 1,306 | -2.87% | 4,800 |
| 24-04-25 | 1,345 | -2.11% | 1,200 |
| 24-04-24 | 1,374 | +3.29% | 1,400 |
| 24-04-23 | 1,330 | -4.04% | 4,700 |
| 24-04-22 | 1,386 | -0.88% | 3,100 |
Delayed Quote NSE India S.E., April 26, 2024 at 07:43 am EDT
More quotes
Beta Drugs Limited is an India-based company, which is engaged in manufacturing of the wide range of anti-cancer drugs in India. The Company operates through manufacturing of Oncology medicines segment. The Company offers a portfolio consisting of approximately 50 products catering to various oncology diseases, including breast, lung, head, and neck, colorectal, ovarian, gastric, brain, testicular renal, prostate, leukemia, lymphoma, myeloma, supportive. The Companyâs oncology portfolio includes various brands, such as AB-PACLI, ADBIRON, ADCARB, ADCIST, Adlante, ADLEAP, ADMIDE, ADOXI, CAPAD, ARBAZ, FISTENT, BUSFAN, Triodelta and others. The Company's subsidiaries include Adley Lab Limited, Adley Formulations Private Limited.
Sector
Pharmaceuticals
Calendar
2024-10-22
- Q2 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -11.13% | 155M | |
| +25.83% | 653B | |
| +27.00% | 556B | |
| -6.76% | 354B | |
| +20.34% | 331B | |
| +3.00% | 296B | |
| +13.09% | 233B | |
| +5.46% | 201B | |
| -9.61% | 193B | |
| -6.26% | 144B |
- Stock Market
- Equities
- BETA Stock
